NO981396D0 - Tetrahydroquinoliner som NMDA antagonister - Google Patents

Tetrahydroquinoliner som NMDA antagonister

Info

Publication number
NO981396D0
NO981396D0 NO981396A NO981396A NO981396D0 NO 981396 D0 NO981396 D0 NO 981396D0 NO 981396 A NO981396 A NO 981396A NO 981396 A NO981396 A NO 981396A NO 981396 D0 NO981396 D0 NO 981396D0
Authority
NO
Norway
Prior art keywords
tetrahydroquinolines
nmda antagonists
nmda
antagonists
Prior art date
Application number
NO981396A
Other languages
English (en)
Other versions
NO981396L (no
NO310355B1 (no
Inventor
Romano Di Fabio
Simone Giacobbe
Barbara Bertani
Fabrizio Micheli
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9519893.3A external-priority patent/GB9519893D0/en
Priority claimed from GBGB9617306.7A external-priority patent/GB9617306D0/en
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of NO981396D0 publication Critical patent/NO981396D0/no
Publication of NO981396L publication Critical patent/NO981396L/no
Publication of NO310355B1 publication Critical patent/NO310355B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO19981396A 1995-09-29 1998-03-27 Tetrahydrokinoliner som NMDA-antagonister, anvendelse derav, fremgangsmåte for fremstilling derav og farmasöytisk preparat NO310355B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9519893.3A GB9519893D0 (en) 1995-09-29 1995-09-29 Heterocyclic compounds
GBGB9617306.7A GB9617306D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds
PCT/EP1996/004206 WO1997012870A1 (en) 1995-09-29 1996-09-26 Tetrahydroquinolines as nmda antagonists

Publications (3)

Publication Number Publication Date
NO981396D0 true NO981396D0 (no) 1998-03-27
NO981396L NO981396L (no) 1998-05-27
NO310355B1 NO310355B1 (no) 2001-06-25

Family

ID=26307841

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981396A NO310355B1 (no) 1995-09-29 1998-03-27 Tetrahydrokinoliner som NMDA-antagonister, anvendelse derav, fremgangsmåte for fremstilling derav og farmasöytisk preparat

Country Status (29)

Country Link
US (1) US5977136A (no)
EP (1) EP0854867B1 (no)
JP (1) JP4108123B2 (no)
KR (1) KR100464895B1 (no)
CN (1) CN1130346C (no)
AP (1) AP876A (no)
AR (1) AR005233A1 (no)
AT (1) ATE221520T1 (no)
AU (1) AU708148B2 (no)
BR (1) BR9610733A (no)
CA (1) CA2232509A1 (no)
CZ (1) CZ292379B6 (no)
DE (1) DE69622731T2 (no)
DK (1) DK0854867T3 (no)
EA (1) EA000875B1 (no)
ES (1) ES2180799T3 (no)
HK (1) HK1009133A1 (no)
HU (1) HUP9900040A3 (no)
IL (1) IL123322A0 (no)
IS (1) IS4677A (no)
MX (1) MX9801967A (no)
NO (1) NO310355B1 (no)
NZ (1) NZ319596A (no)
PL (1) PL186781B1 (no)
PT (1) PT854867E (no)
SI (1) SI0854867T1 (no)
TR (1) TR199800531T1 (no)
TW (1) TW460465B (no)
WO (1) WO1997012870A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
TW555757B (en) * 1998-07-31 2003-10-01 Akzo Nobel Nv Aminomethylcarboxylic acid derivatives
WO2000008018A1 (fr) * 1998-08-07 2000-02-17 Takeda Chemical Industries, Ltd. Derives de benzothiepine, leur procede de preparation et leurs utilisations
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
CA2470578C (en) * 2001-12-28 2010-10-12 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
DE10236910A1 (de) * 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
US7910751B2 (en) * 2005-07-22 2011-03-22 Mochida Pharmaceutical Co., Ltd. Heterocyclidene acetamide derivative
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
PL2268644T3 (pl) 2008-03-05 2012-01-31 Boehringer Ingelheim Int Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania
EP2286808A1 (en) * 2009-08-18 2011-02-23 Rheinische Friedrich-Wilhelms Universität Cytohesin inhibitors
WO2011101774A1 (en) 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
SG183321A1 (en) 2010-02-19 2012-09-27 Boehringer Ingelheim Int Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
WO2016114655A1 (en) * 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
WO2017065602A1 (en) * 2015-10-13 2017-04-20 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders

Also Published As

Publication number Publication date
PT854867E (pt) 2002-12-31
HK1009133A1 (en) 1999-05-28
IS4677A (is) 1998-02-27
TR199800531T1 (xx) 1998-06-22
ES2180799T3 (es) 2003-02-16
JP4108123B2 (ja) 2008-06-25
DE69622731T2 (de) 2003-02-20
NO981396L (no) 1998-05-27
AU7214896A (en) 1997-04-28
AU708148B2 (en) 1999-07-29
CN1202887A (zh) 1998-12-23
HUP9900040A3 (en) 2001-01-29
SI0854867T1 (en) 2003-02-28
US5977136A (en) 1999-11-02
JPH11512728A (ja) 1999-11-02
IL123322A0 (en) 1998-09-24
KR19990063850A (ko) 1999-07-26
WO1997012870A1 (en) 1997-04-10
CA2232509A1 (en) 1997-04-10
PL325966A1 (en) 1998-08-17
CZ94098A3 (cs) 1998-07-15
NZ319596A (en) 1999-09-29
DK0854867T3 (da) 2002-12-02
EA000875B1 (ru) 2000-06-26
TW460465B (en) 2001-10-21
AP9801212A0 (en) 1998-03-31
KR100464895B1 (ko) 2005-05-16
PL186781B1 (pl) 2004-02-27
DE69622731D1 (de) 2002-09-05
EA199800230A1 (ru) 1998-10-29
AR005233A1 (es) 1999-04-28
CN1130346C (zh) 2003-12-10
EP0854867B1 (en) 2002-07-31
EP0854867A1 (en) 1998-07-29
HUP9900040A2 (hu) 1999-04-28
AP876A (en) 2000-09-27
MX9801967A (es) 1998-08-30
BR9610733A (pt) 1999-07-13
ATE221520T1 (de) 2002-08-15
NO310355B1 (no) 2001-06-25
CZ292379B6 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
DK0802910T3 (da) Estrogenagonister/antagonister
EE9600186A (et) Neurokiniini (tahhüülkiniini) antagonistid
DK1009732T3 (da) 1-Amino-alkylcyclohexan NMDA receptor antagonister
NO974463L (no) Anordninger for tele-arbeid
NO961887D0 (no) -adrenergiske agonister
DK0854867T3 (da) Tetrahydroquinoliner som NMDA-antagonister
DK0922034T3 (da) Tetrahydroquinolinderivater som EAA-antagonister
FI961628A0 (fi) Indolijohdannaisia NMDA-antagonisteina
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
NO974043L (no) Indolderivater som EAA-antagonister
ATE309215T1 (de) Nmda (n-methyl-d-aspartate) antagonists
ATA46395A (de) Hängebahn
DK0770603T3 (da) Alkynylphenylaminosulfonylurinstoffer som herbicider
KR970702876A (ko) 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists)
EE9900257A (et) Protsess NMDA antagonistide valmistamiseks
FI970143A0 (fi) Kinoliinijohdannaiset leukotrieeniantagonisteina
SE9502290D0 (sv) New Preparation
FI960434A0 (fi) Slaganordning som arbetar med hydrauliskt tryck
FI940181A0 (fi) Foerfarande foer aostadkommande av en masspektrometer som fungerar under lufttryck
FIU950183U0 (fi) Faerdiggraeddad matsporation avsedd att foertaeras som engaongsportion

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees